Moleculent
Decodes cellular networks to advance human health
$20MUndisclosed
Role not disclosedAV
ARCH Venture Partners
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Europe · Jan 1, 2026
ARCH Venture Partners creates and backs companies built on scientific discoveries, with a healthcare focus on technologies that prevent, detect and treat disease.
The firm works through company formation as well as financing, using a network of partners to translate science into an operating business. It sizes capital to the development requirements, with investments ranging from very early commitments to hundreds of millions of dollars per company.
Its long-term model accommodates scientific programmes that need substantial development before commercial scale. Founders and researchers can engage around the creation of a company, rather than waiting until a conventional growth-stage investment case is established.
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $47M 2 disclosed · full round size, not this investor’s share